B2B BIOLOGY
STRATEGY MEETING EUROPE 2019

Crowne Plaza London Docklands
Wednesday 20TH March, 2019

BIOLOGY

HEAR ABOUT OUR FORMAT

OUR UNIQUE MEETING FORMAT

Roundtable Discussions
These interactive and informal discussion groups are the hallmark of the meeting. Small exclusive groups of Leaders who face shared challenges and strategic priorities are brought together in 60-minute sessions that enable participants to share ideas and lessons learned. Facilitated by experienced professionals, these sessions provide a valuable dialogue with peers on current challenges and topical issues. Each discussion group has limited numbers which ensures each delegate is given ample opportunity to raise questions and contribute to the discussion.

Personalised Agenda
Each delegate receives a personalised agenda combining industry-leading keynote presentations, topical roundtable discussions, networking and business meetings. You only attend sessions and meetings that fit your challenges and interests, ensuring your time out of the office is focused and well-utilised.

One-to-one Meetings
The most effective and time efficient way to assess potential partners at a strategic level. Compare and update your knowledge of the industry in 25-minutes informative and relaxed business meetings with solution providers of your choice.

Networking
Strategic networking opportunities form a key benefit of participating in the meeting. Our proven format for building and strengthening alliances is underscored by a host of networking programmes, from casual networking activities such as lunches as well as formal networking opportunities that are built into your personalised agenda.

Panel Discussion
Industry-leading professionals share their experiences in high-level strategic case study-based presentation.

> *"The roundtable discussion is very great, there are a lot of connections happen and the one-to-one meeting is most important for us, were very happy to meet them personally and connect with them."*
> **- Chief Operating Officer, Bioneeds PLC**

> *"I'm really impressed with the discussion, it is very well quite informed and you've got a lot of key opinions from people. I think the key thing from this meeting is you've got the majority of seniority from Medicinal Chemistry Leaders across European and that's the real power for me."*
> **- Global Head of External Sciences, AztraZeneca**

CONTRIBUTORS TO THE AGENDA

Caroline Barelle
Chief Executive Officer and Chief Scientific Officer
Elasmogen

Klaus Dembowsky
Chief Executive Officer
Amcure

Anna Frostegård
Chief Scientific Officer and Chief Medical Officer
Annexin Pharmaceuticals

Andreas Reichel
Vice President, Head Research Pharmacokinetics
Bayer

Maria Flocco
Vice President, Structure, Biophysics and FBLG
AstraZeneca

Peter Newham
Global Head Oncology Safety
AstraZeneca

Bjarte Furnes
Director and Head of Toxicology
Vifor Pharma

Lassina Badolo
Director Discovery NCE Drug Disposition
Merck Serono

PROVENTA INTERNATIONAL

Proventa International, Unit 51
Skylines Business Village
Limeharbour, London E14 9TS
United Kingdom

+44 20 7096 1222

www.proventainternational.com

B2B BIOLOGY
STRATEGY MEETING EUROPE 2019

Crowne Plaza London Docklands
Wednesday 20TH March, 2019

BIOLOGY

HEAR ABOUT OUR FORMAT

TRACKS	DMPK & ADME	IN VIVO & IN VITRO PHARMACOLOGY	STRUCTURAL BIOLOGY & BIOPHYSICS	TOXICOLOGY	STRATEGIC PARTNERSHIP & OUTSOURCING
08:00-08:30	REGISTRATION & BREAKFAST NETWORKING				
08:30-09:00	WELCOME SPEECH & KEYNOTE PRESENTATION Novel sensor-based bio-imaging tools to lend new insights into biological questions Francis Martin, Chair in Biosciences, University of Central Lancashire				
09:00-10:00	Adoption of ADME models in drug discovery Confirmed for Sponsor	Variability in transporter activity: in vitro and in vivo Michael Symonds, University of Nottingham	Analysing solutions to monitor and optimise protein complexes in structural biology and drug development Facilitator to be Announced	Identifying new tools for safety screening: organs-on-chips, iPSC and 3D cell-based assays, humanized animal models Bjarte Furnes, Vifor Pharma	Engaging with internal customers in a sponsor company to provide a more strategic way of outsourcing and working with a provider Confirmed for Sponsor
10:00-10:05	MORNING BREAK				
10:05-10:30	1-1 MEETINGS / NETWORKING				
10:30-10:35	BREAK				
10:35-11:00	1-1 MEETINGS / NETWORKING				
11:00-12:00	Integrated platform for optimization of ADME Properties of small molecules for drug discovery Andreas Reichel, Bayer	Using in vitro models and open source toxicokinetic databases to support quantitative in vitro to in vivo extrapolation for human risk assessment Confirmed for Sponsor	Structural biology and molecular mechanics of cell guidance signalling Confirmed for Sponsor	Modernizing toxicological risk assessment for compounds released from pharmaceutical, consumer, medical device and combination products: Alternative tools and methods Confirmed for Sponsor	Establishing a new CRO partnership model in support of improved cycle times Confirmed for Sponsor
12:00-12:05	BREAK				
12:05-12:30	1-1 MEETINGS / NETWORKING				
12:30-12:35	BREAK				
12:35-13:00	1-1 MEETINGS / NETWORKING				
13:00-14:00	LUNCH				

PROVENTA INTERNATIONAL

Proventa International, Unit 51
Skylines Business Village
Limeharbour, London E14 9TS
United Kingdom

+44 20 7096 1222

www.proventainternational.com

B2B BIOLOGY
STRATEGY MEETING EUROPE 2019

Crowne Plaza London Docklands
Wednesday 20TH March, 2019

BIOLOGY

HEAR ABOUT OUR FORMAT

TRACKS	DMPK & ADME	IN VIVO & IN VITRO PHARMACOLOGY	STRUCTURAL BIOLOGY & BIOPHYSICS	TOXICOLOGY	STRATEGIC PARTNERSHIP & OUTSOURCING
14:00-14:30	KEYNOTE PRESENTATION				
14:30-15:30	Early ADME and DMPK predictions for better lead optimization Confirmed for Sponsor	Bridging the translational medicine gap between in vitro assays and in vivo drug response assessment Confirmed for Sponsor	Monitoring protein structural changes on a proteome-wide scale Confirmed for Sponsor	Integrating lead optimization and risk assessment strategies Confirmed for Sponsor	Growth in strategic outsourcing and risk sharing-differing models and trends Anna Frostegård, Annexin Pharmaceuticals
15:30-15:35	AFTERNOON BREAK				
15:35-16:00	1-1 MEETINGS / NETWORKING				
16:00-17:00	Predicting human ADME Parameters Lassina Badolo, Merck Serono	Metabolism: An integrative View of in-vitro/in-silico approaches to design new compounds Klaus Dembowsky, Amcure	Next Generation Biophysics in Drug Discovery Maria Flocco, AstraZeneca	Building translational confidence and influence of pre-clinical safety in drug design, selection and development Peter Newham, AstraZeneca	Improving alliances with more effective collaborations Caroline Barelle, Elasmogen
17:00-18:00	DRINKS & CONVERSATION				

PROVENTA INTERNATIONAL

Proventa International, Unit 51
Skylines Business Village
Limeharbour, London E14 9TS
United Kingdom

+44 20 7096 1222

www.proventainternational.com

B2B BIOLOGY
STRATEGY MEETING EUROPE 2019

Crowne Plaza London Docklands
Wednesday 20TH March, 2019

BIOLOGY

HEAR ABOUT OUR FORMAT

DMPK & ADME

Confirmed for Sponsor

09:00-10:00 | Adoption of ADME models in drug discovery

Andreas Reichel
Vice President, Head Research Pharmacokinetics
Bayer

11:00-12:00 | Integrated platform for optimization of ADME Properties of small molecules for drug discovery

- What are the strengths and limitations of ADME screening and compound optimisation today? What are the key challenges for efficient LO guidance?
- How to select the optimal screening strategy to meet the candidate drug target profile?
- How to rationally make use of high dimensional data to guide LO toward high quality candidates? What should be adapted for new modalities bRo5?
- How do you integrate M&S to guide lead optimisation towards candidates with improved clinical success? How do you build up translational confidence?
- What are the new technologies in the area? What is missing? Is there anything with disruptive potential on the horizon?

Confirmed for Sponsor

14:30-15:30 | Early ADME and DMPK predictions for better lead optimization

Lassina Badolo
Director Discovery NCE Drug Disposition
Merck Serono

16:00-17:00 | Predicting human ADME Parameters

- The candidate drug target profile
- The relationship between PK and PD
- The key optimization parameters
- The right screening plan

PROVENTA INTERNATIONAL

Proventa International, Unit 51
Skylines Business Village
Limeharbour, London E14 9TS
United Kingdom

+44 20 7096 1222

www.proventainternational.com

B2B BIOLOGY
STRATEGY MEETING EUROPE 2019

Crowne Plaza London Docklands
Wednesday 20TH March, 2019

BIOLOGY

HEAR ABOUT OUR FORMAT

IN VIVO & IN VITRO PHARMACOLOGY

Michael Symonds
Professor of Developmental Physiology
The University of Nottingham

09:00-10:00 **Variability in transporter activity: in vitro and in vivo**

- Why target nutrient transporters and what endpoints should be used?
- In vitro vs in vivo activity – which cell models and organ systems should be targeted?
- Credible models – what are the key determinants of the physiological vs pathological state?
- The use of 'omics, arrays and deep sequencing

Confirmed for Sponsor

14:30-15:30 **Bridging the translational medicine gap between in vitro assays and in vivo drug response assessment**

Confirmed for Sponsor

11:00-12:00 **Using in vitro models and open source toxicokinetic databases to support quantitative in vitro to in vivo extrapolation for human risk assessment**

Klaus Dembowsky
Chief Executive Officer
Amcure

16:00-17:00 **Metabolism: An integrative View of in-vitro/in-silico approaches to design new compounds**

- Did the computational/in-silico methods live up to the promise to increase productivity in research and development
- Organ on a chip technology – where do we stand? Impact?
- Impact on development (e.g. attrition, speed) versus drug discovery (e.g. creativity).
- Will artificial intelligence change the scene?

PROVENTA INTERNATIONAL

Proventa International, Unit 51
Skylines Business Village
Limeharbour, London E14 9TS
United Kingdom

+44 20 7096 1222

www.proventainternational.com

B2B BIOLOGY
STRATEGY MEETING EUROPE 2019

Crowne Plaza London Docklands
Wednesday 20TH March, 2019

BIOLOGY

HEAR ABOUT OUR FORMAT

STRUCTURAL BIOLOGY & BIOPHYSICS

Facilitator to be Announced

09:00-10:00 | Analysing solutions to monitor and optimise protein complexes in structural biology and drug development

Confirmed for Sponsor

11:00-12:00 | Structural biology and molecular mechanics of cell guidance signalling

Confirmed for Sponsor

14:30-15:30 | Monitoring protein structural changes on a proteome-wide scale

Maria Flocco

Vice President, Structure, Biophysics and FBLG
AstraZeneca

16:00-17:00 | Next Generation Biophysics in Drug Discovery

- What are the strengths and limitations of the established biophysical methods in drug discovery.
- Key challenges in making macromolecular complexes and cells amenable to biophysical analysis.
- Novel biophysical approaches with the potential to make significant impact in drug discovery

PROVENTA INTERNATIONAL

Proventa International, Unit 51
Skylines Business Village
Limeharbour, London E14 9TS
United Kingdom

+44 20 7096 1222

www.proventainternational.com

B2B BIOLOGY
STRATEGY MEETING EUROPE 2019

Crowne Plaza London Docklands
Wednesday 20TH March, 2019

BIOLOGY

HEAR ABOUT OUR FORMAT

TOXICOLOGY

Bjarte Furnes
Director and Head of Toxicology
Vifor Pharma

09:00-10:00 **Identifying new tools for safety screening: organs-on-chips, iPSC and 3D cell-based assays, humanized animal models**

- Impact of new tools for safety screening on drug pipeline: widen or narrow?
- Cost of new tools vs. historically available tools
- Current regulatory acceptance
- The future: established alternative methods or continued evolvement of new methods

Confirmed for Sponsor

14:30-15:30 **Integrating lead optimization and risk assessment strategies**

Confirmed for Sponsor

11:00-12:00 **Modernizing toxicological risk assessment for compounds released from pharmaceutical, consumer, medical device and combination products: Alternative tools and methods**

Peter Newham
Global Head Oncology Safety
AstraZeneca

16:00-17:00 **Building translational confidence and influence of pre-clinical safety in drug design, selection and development**

- How can safety and metabolism studies maximise the chances of discovering successful drugs?
- How can we building translational confidence in silico and in vitro assays (eg MPS models) such that they impact on med-chem design and lead selection?
- How are quantitative pharmacology/toxicology models impacting on risk assessment and informing clinical development with respect to safety?
- Can high dimensional data (high content biology, transcriptomics, proteomics, metabolomics) make a difference?
- Is pre-competitive data sharing desirable and possible to improve drug safety prediction?

PROVENTA INTERNATIONAL

Proventa International, Unit 51
Skylines Business Village
Limeharbour, London E14 9TS
United Kingdom

+44 20 7096 1222

www.proventainternational.com

B2B BIOLOGY
STRATEGY MEETING EUROPE 2019

Crowne Plaza London Docklands
Wednesday 20TH March, 2019

BIOLOGY

HEAR ABOUT OUR FORMAT

STRATEGIC PARTNERSHIP & OUTSOURCING

Confirmed for Sponsor

09:00-10:00 | Engaging with internal customers in a sponsor company to provide a more strategic way of outsourcing and working with a provider

Confirmed for Sponsor

11:00-12:00 | Establishing a new CRO partnership model in support of improved cycle times

Anna Frostegård
Chief Scientific Officer and Chief Medical Officer
Annexin Pharmaceuticals

14:30-15:30 | Growth in strategic outsourcing and risk sharing- differing models and trends

- Shifts in the R&D landscape-consequences for partnerships
- Increasingly virtualized R&D models-growth in strategic outsourcing
- Rapid decision making and reallocation of resources
- Risk sharing

Caroline Barelle
Chief Executive Officer and Chief Scientific Officer
Elasmogen

16:00-17:00 | Improving alliances with more effective collaborations

- Setting the scene; What are the expectations from each partner?; What are their drivers?; What is the endgame?
- The time paradigm; The clock ticks faster the smaller the biotech – how do we align the pace?
- Communicating in a well-connected world; Email overload – implementing more effective means of keeping the channels open. What works best?
- How do we keep the relationship going?; Can we identify and foresee problems before they become issues both from a technical and cultural perspective?

PROVENTA INTERNATIONAL

Proventa International, Unit 51
Skylines Business Village
Limeharbour, London E14 9TS
United Kingdom

+44 20 7096 1222

www.proventainternational.com

B2B BIOLOGY
STRATEGY MEETING EUROPE 2019

Crowne Plaza London Docklands
Wednesday 20TH March, 2019

BIOLOGY

HEAR ABOUT OUR FORMAT

WHO SHOULD ATTEND?

Thought leaders who will benefit from attending include:

Chief Executive Officers
Senior Vice Presidents
Executive Vice Presidents
Vice Presidents
Executive Directors
Directors
Global Heads

Responsible for:

DMPK
Computational
Drug metabolism
ADME Toxicologist
PK/PD modeling
Toxicologist
Anatomy
Stem cell
Structural Biology and Biophysics
Indication Expansion
Strategic Partnerships and Alliances
Global Commercialization/Strategy
Program and Portfolio Development
Strategy and Portfolio Solutions

PROVENTA INTERNATIONAL

Proventa International, Unit 51
Skylines Business Village
Limeharbour, London E14 9TS
United Kingdom

+44 20 7096 1222
www.proventainternational.com

B2B BIOLOGY
STRATEGY MEETING EUROPE 2019

Crowne Plaza London Docklands
Wednesday 20TH March, 2019

BIOLOGY

HEAR ABOUT OUR FORMAT

2019 SPONSORS

ASSOCIATE SPONSOR

WuXi AppTec is a leading pharmaceutical, biopharmaceutical, and medical device open-access platform global company. As an innovationdriven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services that enables drug and medical device R&D through cost-effective and efficient solutions. WuXi's Oncology Unit possesses world leading oncology and immuno-oncology platforms providing a comprehensive panel of tumor model systems, including human cancer cell line-derived xenograft models, murine syngeneic tumor models, humanized animal models and patient-derived xenograft (PDX) models with in-depth genomic characterization. Our proprietary database – OncoWuXi – has over 1,200 tumor models with full annotation. WuXi Oncology also has strong expertise in CRISPR and specialized tumor cell biology assays.

CO-HOST SPONSORS

Synovo

Dotmatics delivers a ready-to-use platform to capture, register, share, collaborate, query, visualise and analyse all the information and knowledge generated in the modern, highly collaborative scientific industries. Dotmatics has significant expertise in scientific informatics, including database management for chemistry and biologics, electronic laboratory notebooks, chemical and biological registration, screening data management, SAR analysis, reporting, and visualisation.

Sygnature Discovery is the UK's largest independent provider of integrated drug discovery resource. We accelerate the search for new medicines by providing flexible scientific resource and advanced drug discovery knowledge and expertise.
Core capabilities include medicinal chemistry, in vitro bioscience, computational chemistry, DMPK, physical sciences and informatics; all co-located in our superb technologically advanced facility.
Our experienced and highly qualified PhD scientists utilize novel technologies and innovative ways of working to ensure that we successfully deliver on your most complex integrated research programmes.

PROVENTA INTERNATIONAL

Proventa International, Unit 51
Skylines Business Village
Limeharbour, London E14 9TS
United Kingdom

+44 20 7096 1222

www.proventainternational.com

B2B BIOLOGY
STRATEGY MEETING EUROPE 2019

Crowne Plaza London Docklands
Wednesday 20TH March, 2019

BIOLOGY

HEAR ABOUT OUR FORMAT

HOTEL & TRAVEL



VENUE

Crowne Plaza London Docklands
Royal Victoria Dock, Western Gateway,
London E16 1AL, UK

To make an individual room reservation, please do contact Crowne Plaza Reservation Department under.

PHONE: +44 20 7055 2101
EMAIL: group@cpdocklands.co.uk

DISCOUNT ROOM RATES

Single Occupancy: **$ 219**
Double Occupancy: **$ 229**

DISCOUNT ROOM RATE CUT OFF

18TH February, 2019

Proventa Code: PI4

MAP & DIRECTIONS

PROVENTA INTERNATIONAL

Proventa International, Unit 51
Skylines Business Village
Limeharbour, London E14 9TS
United Kingdom

+44 20 7096 1222

www.proventainternational.com